Article
Immunology
Jie Wu, Liang Lv, Chunlian Wang
Summary: The meta-analysis examined the efficacy of fecal microbiota transplantation (FMT) in irritable bowel syndrome (IBS) and found inconsistent results. FMT administered via colonoscopy or gastroscope may benefit IBS patients and improve their quality of life. However, the quality of evidence supporting the use of FMT in IBS is very low.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Review
Medicine, General & Internal
Chatpol Samuthpongtorn, Piyawat Kantagowit, Rapat Pittayanon, Tanisa Patcharatrakul, Sutep Gonlachanvit
Summary: Fecal microbiota transplantation (FMT) significantly improved short-term symptoms of IBS-SSS and IBS-QoL in IBS patients. However, there was no significant improvement in global symptoms. Well-defined donors and appropriate fecal administration routes appear to be important factors for the successful outcomes of FMT in IBS.
FRONTIERS IN MEDICINE
(2022)
Review
Immunology
Mancai Wang, Xiaofeng Xie, Songbo Zhao, Xiaojuan Ma, Zheyuan Wang, Youcheng Zhang
Summary: This systematic review and meta-analysis found that a single stool FMT is effective and safe for patients with IBS. However, the effectiveness of FMT may be influenced by certain factors, and the relationship between the gut microbiome and the effect of FMT for IBS remains unclear.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Medicine, General & Internal
Tania Rodrigues, Sofia Rodrigues Fialho, Joao Ricardo Araujo, Rita Rocha, Andre Moreira-Rosario
Summary: A systematic review and subgroup analysis showed that fecal microbial transplantation (FMT) may be an effective treatment for irritable bowel syndrome (IBS), especially through gastroscopy or nasojejunal tube. Furthermore, FMT appears to be more effective for IBS patients with constipation symptoms, and the freshness of the fecal transplant and bowel preparation also influence FMT efficacy.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Parnian Jamshidi, Yeganeh Farsi, Zahra Nariman, Mohammad Reza Hatamnejad, Benyamin Mohammadzadeh, Hossein Akbarialiabad, Mohammad Javad Nasiri, Leonardo A. Sechi
Summary: This systematic review and meta-analysis examined the effectiveness of fecal microbiota transplantation (FMT) in relieving symptoms in patients with irritable bowel syndrome (IBS). The study found that a single dose of multiple-donor FMT administered via colonoscopy significantly improved patient symptoms compared with autologous FMT used as a placebo. However, other treatment methods did not show significant benefits. Further research and experimental studies are needed to better understand the underlying mechanisms of FMT for IBS.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Gastroenterology & Hepatology
Sofie Ingdam Halkjaer, Bobby Lo, Frederik Cold, Alice Hojer Christensen, Savanne Holster, Julia Konig, Robert Jan Brummer, Olga C. Aroniadis, Perttu Lahtinen, Tom Holvoet, Lise Lotte Gluud, Andreas Munk Petersen
Summary: Fecal microbiota transplantation (FMT) has been suggested as a treatment for irritable bowel syndrome (IBS), but the efficacy and safety of FMT for IBS remain unclear. This review found insufficient evidence to support or refute the use of FMT for IBS. Larger trials are needed to further evaluate its effectiveness.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Nutrition & Dietetics
Hui-jun Zhao, Xiao-jing Zhang, Na-na Zhang, Bin Yan, Ke-ke Xu, Li-hua Peng, Fei Pan
Summary: This article conducted a meta-analysis to evaluate the efficacy and safety of fecal microbiota transplantation (FMT) for the treatment of irritable bowel syndrome (IBS) patients. The results showed that FMT did not significantly improve the overall symptoms of IBS patients, but FMT operated through invasive routes significantly improved global IBS symptoms, while FMT delivered via oral capsules had a negative impact on IBS patients.
FRONTIERS IN NUTRITION
(2022)
Letter
Gastroenterology & Hepatology
Yuka Ikeda, Kurumi Taniguchi, Haruka Sawamura, Ai Tsuji, Satoru Matsuda
Summary: Irritable bowel syndrome is an important health concern that may be linked to alterations in the microbiota of the gut-brain axis. Dietary intake can contribute to the production of D-amino acids, which play key roles in cellular physiological processes against oxidative stresses. The gut microbiota may have significant effects on emotional stability through the action of D-amino acids.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Medicine, General & Internal
Sergii Tkach, Andrii Dorofeyev, Iurii Kuzenko, Oksana Sulaieva, Tetyana Falalyeyeva, Nazarii Kobyliak
Summary: This study found that fecal microbiota transplantation (FMT) can significantly improve symptoms in patients with post-infectious irritable bowel syndrome (PI-IBS) and has better safety and tolerability compared to traditional pharmacotherapy.
FRONTIERS IN MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Di Zhang, Yan Tang, Xiangyu Bai, Da Li, Mengxue Zhou, Chunmei Yu, Hua Wu
Summary: The aim of this study was to gather, assess, and synthesize evidence on fecal microbiota transplantation (FMT) for irritable bowel syndrome (IBS). The results showed that there is currently insufficient evidence to determine whether FMT has a more beneficial effect on IBS patients compared to placebo treatment. Well-designed, larger trials are needed to provide more evidence in this field and to determine the optimal donor selection, route of administration, dosage, and frequency.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Adrian Boicean, Victoria Birlutiu, Cristian Ichim, Paula Anderco, Sabrina Birsan
Summary: Inflammatory bowel diseases (IBD) are complex diseases characterized by chronic inflammation in the gastrointestinal tract. Fecal microbiota transplantation (FMT) has shown increasing effectiveness and safety in treating recurrent Clostridium difficile infection (CDI) and co-infection of SARS-CoV-2 and CDI. By modifying the gut microbiota, FMT offers an alternative approach to indirectly influence the host's immune system in a safe way, improving clinical symptoms and endoscopic findings in IBD patients. Further validation is needed to establish a clinical protocol for FMT in IBD.
Article
Medicine, General & Internal
Jiaqu Cui, Zhiliang Lin, Hongliang Tian, Bo Yang, Di Zhao, Chen Ye, Ning Li, Huanlong Qin, Qiyi Chen
Summary: This study aimed to investigate the long-term efficacy of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome (IBS). The results from a 60-month follow-up period established the safety and efficacy of FMT for IBS, but highlighted the need for periodic and repetitive treatments to maintain the sustained effect.
FRONTIERS IN MEDICINE
(2021)
Article
Multidisciplinary Sciences
Binbin Tang, Yunlian Hu, Jianhui Chen, Chengxia Su, Qian Zhang, Chaoqun Huang
Summary: This study investigated the characteristics and correlation between oral (tongue coating) and fecal microbiota in patients with diarrheal irritable bowel syndrome (IBS-D). The microbial richness of tongue coating in IBS-D patients was lower than that in the normal control group. The oral and fecal microbiotas of IBS-D patients differ from those of the control group.
Review
Medicine, General & Internal
Qin Chen, Zhiyun Zhang, Shaosheng Bei, Xiaofeng Wang, Yunying Zhu
Summary: This article evaluated the efficacy and safety of oral capsule fecal microbiota transplantation in the treatment of recurrent bowel disease, providing more comprehensive evidence for this treatment approach.
Review
Gastroenterology & Hepatology
Theodore Rokkas, Georgina L. Hold
Summary: This study used network meta-analysis to compare the relative effectiveness and safety of different fecal microbiota transplantation (FMT) modalities in the treatment of Irritable Bowel Syndrome (IBS). The results showed that overall, FMT was not more effective than placebo, but subgroup analysis showed that FMT via duodenoscope and nasojejunal tube were effective. Therefore, more well-designed clinical trials are needed to ensure the efficacy and safety of FMT before it can be applied in everyday clinical practice for IBS patients.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2023)